Melanoma

© Getty Images

IO Biotech enrolls 380 Patients in phase 3 advanced melanoma trial

By Isabel Cameron

IO Biotech, a clinical-stage biopharma company developing therapeutic cancer vaccines, has completed enrollment in its phase 3 trial for IO102-IO103, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced melanoma....